Simvastatin local drug delivery in smokers with chronic periodontitis: a randomized controlled clinical trial.
Aust Dent J
; 58(2): 156-62, 2013 Jun.
Article
en En
| MEDLINE
| ID: mdl-23713634
ABSTRACT
BACKGROUND:
Simvastatin (SMV) is a specific competitive inhibitor of 3-hydroxy-2-methyl-glutaryl coenzyme A reductase. Statins have recently been shown to promote bone formation. This study was designed to investigate the effectiveness of SMV 1.2% in an indigenously prepared biodegradable controlled release gel as an adjunct to scaling and root planing (SRP) in the treatment of smokers with chronic periodontitis.METHODS:
Forty patients were categorized into two treatment groups SRP plus SMV 1.2% and SRP plus placebo. Clinical parameters were recorded at baseline and at 3, 6 and 9 months; they included modified sulcus bleeding index (mSBI), probing depth (PD) and clinical attachment level (CAL). At baseline, after 6 months and 9 months, radiologic assessment of intrabony defect (IBD) fill was done using computer-aided software.RESULTS:
Mean probing depth reduction and mean clinical attachment level gain was greater in the SMV group than the placebo group at all visits. Furthermore, significantly greater mean percentage of bone fill was found in the SMV group (32.37 ± 10.23%) compared to the placebo (4.18 ± 5.39%).CONCLUSIONS:
There was a greater decrease in mSBI and PD and more CAL gain with significant IBD fill at sites treated with SRP plus locally delivered SMV in smokers with chronic periodontitis.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fumar
/
Índice Periodontal
/
Pérdida de Hueso Alveolar
/
Raspado Dental
/
Simvastatina
/
Conservadores de la Densidad Ósea
/
Periodontitis Crónica
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Aust Dent J
Año:
2013
Tipo del documento:
Article
País de afiliación:
India